Division of Epidemiology & Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Rondebosch, South Africa
Centre for Infectious Disease Epidemiology, University of Cape Town, Rondebosch, South Africa.
Sex Transm Infect. 2022 Nov;98(7):484-491. doi: 10.1136/sextrans-2021-055057. Epub 2021 Dec 9.
STIs remain a global public health problem with a high burden among pregnant women. STIs in pregnant women may lead to various adverse pregnancy outcomes. In most sub-Saharan African countries, syndromic management is used for screening and treatment of STIs. We aimed to update and summarise pooled prevalence of curable STIs and bacterial vaginosis (BV) among pregnant women in sub-Saharan Africa.
Electronic databases and reference lists of relevant published and unpublished studies were searched from March 2015 to October 2020. Studies were included if they (CT), (TV), (NG), (syphilis), (MG) and BV among pregnant women in sub-Saharan Africa. Meta-analyses were performed with observed prevalences corrected for diagnostic errors to estimate the pooled prevalence of diagnosed infections by region.
A total of 48 studies met the inclusion criteria, providing 85-point prevalence estimates for curable STIs and BV. Pooled prevalence estimates (with 95% CI and number of women tested) were as follows: MG: 13.5% (4.0-27.2, n=1076); CT: 10.8% (6.9-15.5, n=6700); TV: 13.8% (10.0-18.0, n=9264); NG: 3.3% (2.1-4.7, n=6019); syphilis: 2.9% (2.0-4.0, n=95 308) and BV: 36.6% (27.1-46.6, n=5042). By region, BV was the most prevalent and ranged from 28.5% (24.5-32.8, n=1030) in Eastern Africa to 52.4% (33.5-70.9, n=2305) in Southern Africa; NG had the lowest prevalence, ranging from 1.4% (95% CI 0.1 to 3.1, n=367) in Central Africa to 4.4% (95% CI 2.6 to 6.4, n=4042) in Southern Africa.
The prevalence of curable STIs and BV in sub-Saharan Africa is substantial in pregnant women but most prevalent in Southern Africa where HIV prevalence is highest. It is crucial to integrate screening of curable STIs into antenatal care programmes that have previously focused on diagnosis and treatment of syphilis and HIV.
性传播感染仍然是全球公共卫生问题,孕妇负担沉重。孕妇中的性传播感染可能导致各种不良妊娠结局。在大多数撒哈拉以南非洲国家,采用综合征管理方法对性传播感染进行筛查和治疗。我们旨在更新和总结撒哈拉以南非洲孕妇中可治愈性传播感染和细菌性阴道病(BV)的合并患病率。
从 2015 年 3 月至 2020 年 10 月,对电子数据库和相关已发表和未发表研究的参考文献列表进行了搜索。如果研究符合以下标准,则将其纳入:(1)在撒哈拉以南非洲进行的横断面、前瞻性或回顾性研究;(2)报告了孕妇中可治愈性传播感染(包括沙眼衣原体[CT]、淋病奈瑟菌[NG]、梅毒[syphilis]、解脲支原体[MG]和细菌性阴道病[BV])的患病率;(3)使用适当的诊断方法进行检测。使用观察到的患病率进行荟萃分析,并校正诊断错误,以估计按地区诊断感染的合并患病率。
共有 48 项研究符合纳入标准,提供了可治愈性传播感染和 BV 的 85 点患病率估计值。合并患病率估计值(95%CI 和接受检测的妇女数量)如下:MG:13.5%(4.0-27.2,n=1076);CT:10.8%(6.9-15.5,n=6700);TV:13.8%(10.0-18.0,n=9264);NG:3.3%(2.1-4.7,n=6019);梅毒:2.9%(2.0-4.0,n=95308)和 BV:36.6%(27.1-46.6,n=5042)。按地区划分,BV 是最常见的,从东部非洲的 28.5%(24.5-32.8,n=1030)到南部非洲的 52.4%(33.5-70.9,n=2305);NG 的患病率最低,从中部非洲的 1.4%(95%CI 0.1-3.1,n=367)到南部非洲的 4.4%(95%CI 2.6-6.4,n=4042)。
撒哈拉以南非洲孕妇中可治愈性传播感染和 BV 的患病率相当高,但在 HIV 患病率最高的南部非洲最为普遍。将可治愈性传播感染的筛查纳入以前专注于梅毒和 HIV 诊断和治疗的产前保健方案至关重要。